Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brandon Morehead

Physician Assistant, Medical Paducah, KY Physician Assistant

NPI 1063088300 CMS profile 11306003

2520 New Holt Rd Ste I, Paducah, KY 42001

Open in the dashboard

General payments

$5,601

360 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brandon Morehead of Paducah, KY is reported in the CMS Open Payments database as having received $5,601 across 360 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,040 176
2024 General $1,280 84
2023 General $780 62
2022 General $431 34
2021 General $70 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandon Morehead
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Brandon Morehead were reported at $3,040. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Brandon Morehead Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $70 $156 $41–$563 $132
2022 $431 $185 $55–$649 $149
2023 $780 $199 $58–$717 $160
2024 $1,280 $206 $62–$740 $164
2025 $3,040 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ITI, Inc. $1,043 86 payments
  2. AbbVie, Inc. $931 84 payments
  3. Otsuka America Pharmaceutical, Inc. $646 34 payments
  4. Teva Pharmaceuticals USA, Inc. $508 17 payments
  5. Supernus Pharmaceuticals, Inc. $417 22 payments
  6. Janssen Pharmaceuticals, Inc $271 18 payments
  7. Alkermes, Inc. $221 14 payments
  8. E.R. Squibb & Sons, L.L.C. $208 15 payments
  9. Vanda Pharmaceuticals Inc. $199 12 payments
  10. Axsome Therapeutics, Inc. $163 8 payments
  11. Other $993 50 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,404 354 payments
  2. Consulting Fee $115 1 payment
  3. Education $82 5 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $714 59 payments
  2. CAPLYTA Psychiatry $530 50 payments
  3. CAPLYTA Psychiatry $513 36 payments
  4. REXULTI $493 24 payments
  5. SPRAVATO $386 19 payments
  6. Qelbree $373 19 payments
  7. ABILIFY MAINTENA $297 19 payments
  8. Austedo XR $285 6 payments
  9. UZEDY $222 11 payments
  10. VRAYLAR Neuroscience $218 25 payments
  11. Other $2,789 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

3,363

Median for Physician Assistant: 241

Drug cost

$269,498

Median for Physician Assistant: $4,110

Branded share of claims

18.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 22 $48,429
Vraylar Cariprazine Hcl Brand 29 $42,674
Invega Sustenna Paliperidone Palmitate Brand 12 $28,657
Caplyta Lumateperone Tosylate Brand 15 $24,392
Lurasidone Hcl Generic 67 $24,067
Spravato Esketamine Hcl Brand 18 $23,554
Trintellix Vortioxetine Hydrobromide Brand 31 $17,527
Auvelity Dextromethorphan Hbr/Bupropion Brand 14 $14,949
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 50 $6,544
Paliperidone Er Paliperidone Brand 11 $3,844

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $393
$393 29 —
CAPLYTA
  • ITI, Inc. $168
$168 15 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $100
  • Lundbeck LLC $30
$130 22 —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $80
$80 18 —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

360 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record